A. Ionescu-Stoian *, Adriana Mihăilescu *
* Dr. Alexandru Ionescu-Stoian – doctor în medicină, CSP I, Chim. Adriana Mihăilescu – CSP II, Centrul de Cercetări Stiinţifice Medico-Militare, Bucureşti
Abstract
The I, imidazoline receptor is a new target of centrallyacting antihyptensives and is primarily responsible for the blood pressure lowering action of these drugs. Alpha-2-adrenoreceptors activation are implicated in the adverse effects of older centrally-acting antihypertensive agents, causing dry mouth, sedation and rebound on discountinuing treatment. The agonists of I, imidazoline receptor lower eievated blood pressure in a similar manner as the older centrallyacting antihypertensives, but to be associated with a lower incidence of adverse effects compared to clonidine.